The American Society of Clinical Oncology has recently updated its clinical practice guidelines for the management of initial hormone therapy with men with advanced P.C. The guide line panel found that there is a 17% reduction in the mortality rate from prostate cancer if hormone therapy is started early in the disease process, however, the [...]
Clarifying the Issues Surrounding Dendreon's Provenge Posted on Apr 16th, 2007 with stocks: DNDN Wall Diver submits: Rebuttal to article, "Dendreon's Provenge Apart by ODAC Member": On April 13, 2007, in Volume 33, No. 14 of The Cancer Letter, a letter was published which the Editor, Paul Goldberg, attributed to Howard Scher, MD, of the [...]
Dr. Howard Scher, M.D. was one of the four members of the Provenge advisory committee who voted against recommending that the FDA approve Provenge. Dr. Scher is a respected clinician (practicing at Sloane Kettering Hospital) and researcher. I do believe that his letter contributes to the discussion about Povenge and so I have chosen to [...]
Last Thursday, March 29, 2007, I had the opportunity to participate as a patient advocate in the FDA's Tissue, and Gene Therapies Advisory Committee. The purpose of the committee meeting was to evaluate the application of Dendreon Corp for approval of their new drug, Sipuleucel-T (Provenge). I want to clarify the facts and dispel some [...]